| This article has been cited by |
| 1 | Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in MetastaticBRAF-Mutant Melanoma | |
| Jean-Pierre Delord,Caroline Robert,Marta Nyakas,Grant A. McArthur,Ragini Kudchakar,Amit Mahipal,Yasuhide Yamada,Ryan Sullivan,Ana Arance,Richard F. Kefford,Matteo S. Carlino,Manuel Hidalgo,Carlos Gomez-Roca,Daniela Michel,Abdelkader Seroutou,Vassilios Aslanis,Giordano Caponigro,Darrin D. Stuart,Laure Moutouh-de Parseval,Tim Demuth,Reinhard Dummer |
| Clinical Cancer Research.2017;23(18)5339 |
| [DOI] |
|
| 2 | Vemurafenib | |
| Jean-Pierre Delord,Caroline Robert,Marta Nyakas,Grant A. McArthur,Ragini Kudchakar,Amit Mahipal,Yasuhide Yamada,Ryan Sullivan,Ana Arance,Richard F. Kefford,Matteo S. Carlino,Manuel Hidalgo,Carlos Gomez-Roca,Daniela Michel,Abdelkader Seroutou,Vassilios Aslanis,Giordano Caponigro,Darrin D. Stuart,Laure Moutouh-de Parseval,Tim Demuth,Reinhard Dummer |
| Reactions Weekly.2014;1507(1)30 |
| [DOI] |
|
| 3 | Neurological complications of new chemotherapy agents | |
| Alicia M Zukas,David Schiff |
| Neuro-Oncology.2018;20(1)24 |
| [DOI] |
|
| 4 | Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study | |
| Carlen Yuen,Pankti Reid,Zuoli Zhang,Betty Soliven,Jason J. Luke,Kourosh Rezania |
| Journal of Immunotherapy.2019;42(3)94 |
| [DOI] |
|
| 5 | Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review | |
| Shruthi Harish Bindiganavile,Nita Bhat,Andrew G. Lee,Dan S. Gombos,Nagham Al-Zubidi |
| Journal of Immunotherapy and Precision Oncology.2021;4(1)6 |
| [DOI] |
|
| 6 | Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact | |
| Nicholas S. Phillips,Elizabeth S. Duke,Hannah-Lise T. Schofield,Nicole J. Ullrich |
| Journal of Clinical Oncology.2021;39(16)1752 |
| [DOI] |
|
| 7 | Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan | |
| H. Uhara,Y. Kiyohara,A. Tsuda,M. Takata,N. Yamazaki |
| Clinical and Translational Oncology.2018;20(2)169 |
| [DOI] |
|
| 8 | Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib | |
| Annette Compter,Willem Boogerd,Johannes V. van Thienen,Dieta Brandsma |
| Neurology: Clinical Practice.2017;7(5)418 |
| [DOI] |
|
| 9 | Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage
III
melanoma | |
| Andrew T. Li,Aung Min Maw,Edward Hsiao,Sydney Ch'ng,Georgina V. Long,Kerwin F. Shannon,Edwin J. Morrison |
| ANZ Journal of Surgery.2022;92(1-2)247 |
| [DOI] |
|
| 10 | Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage
III
melanoma | |
| Gilbert Youssef,Patrick Y. Wen,Eudocia Q. Lee |
| ANZ Journal of Surgery.2022;92(1-2)479 |
| [DOI] |
|
| 11 | Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage
III
melanoma | |
| Ramak Ajideh,Hanieh Kamyab,Mohammad Hossein Yazdi |
| ANZ Journal of Surgery.2022;92(1-2)479 |
| [DOI] |
|
| 12 | Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage
III
melanoma | |
| Frederick “Fritz” T. Fraunfelder,Frederick “Rick” W. Fraunfelder |
| ANZ Journal of Surgery.2021;92(1-2)299 |
| [DOI] |
|
| 13 | Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature | |
| Chiara Demichelis,Andrea Balestra,Caterina Lapucci,Angela Zuppa,Stefano G Grisanti,Valeria Prada,Giampaola Pesce,Ilaria Grasso,Paola Queirolo,Angelo Schenone,Luana Benedetti,Marina Grandis |
| Neurological Sciences.2021;42(4)1405 |
| [DOI] |
|
| 14 | Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma | |
| C. Velter,C. Libenciuc,E. Routier,C. Mateus,J. Fahmy,L. Ghoufi,O. Lambotte,A. Not,C. Cauquil,S. Claveau,J. Claveau,C. Robert |
| European Journal of Cancer.2019;111(4)8 |
| [DOI] |
|
| 15 | Ocular Toxicity of Targeted Anticancer Agents | |
| Blake H. Fortes,Prashant D. Tailor,Lauren A. Dalvin |
| Drugs.2021;81(7)771 |
| [DOI] |
|
